Intricon (IIN) 10-Q22 May 202020 Q1 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	1-5005
Entity Registrant Name	INTRICON CORP
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1069060
Entity Address, Address Line One	1260 Red Fox Road
Entity Address, City or Town	Arden Hills
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55112
City Area Code	651
Local Phone Number	636-9770
Title of 12(b) Security	Common stock, par value $1.00 per share
Trading Symbol	IIN
Security Exchange Name	NASDAQ
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		8,821,752
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Central Index Key	0000088790

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 15,177	$ 8,523
Restricted cash	616	639
Short-term investment securities	16,889	23,451
Accounts receivable, less allowance for doubtful accounts of $331 at March 31, 2020 and $325 at December 31, 2019	8,241	8,993
Inventories	19,115	16,377
Contract assets	10,079	10,237
Other current assets	1,426	1,975
Current assets of discontinued operations		80
Total current assets	71,543	70,275
Machinery and equipment	42,944	41,073
Less: Accumulated depreciation	28,213	27,522
Net machinery and equipment	14,731	13,551
Goodwill	9,551	9,551
Operating lease right-of-use assets, net	3,862	4,372
Investment in partnerships	750	1,160
Long-term investments securities	5,379	8,629
Other assets, net	5,902	6,055
Total assets	111,718	113,593
Current liabilities:
Current financing leases	88	101
Current operating leases	1,605	1,729
Accounts payable	10,392	9,876
Accrued salaries, wages and commissions	2,736	2,274
Other accrued liabilities	2,474	2,869
Liabilities of discontinued operations		77
Total current liabilities	17,295	16,926
Noncurrent financing leases	15	30
Noncurrent operating leases	2,503	2,937
Other postretirement benefit obligations	371	382
Accrued pension liabilities	651	655
Other long-term liabilities	2,106	2,171
Total liabilities	22,941	23,101
Commitments and contingencies (Note 15)
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,819 and 8,781 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	8,819	8,781
Additional paid-in capital	86,978	86,770
Accumulated deficit	(6,265)	(4,286)
Accumulated other comprehensive loss	(502)	(520)
Total shareholders' equity	89,030	90,745
Non-controlling interest	(253)	(253)
Total equity	88,777	90,492
Total liabilities and equity	$ 111,718	$ 113,593

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Consolidated Condensed Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 331	$ 325
Common stock, par value	$ 1	$ 1
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	8,819,000	8,781,000
Common stock, shares outstanding	8,819,000	8,781,000

Consolidated Condensed Statemen

Consolidated Condensed Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Consolidated Condensed Statements Of Operations [Abstract]
Revenue, net	$ 21,503	$ 29,570
Cost of goods sold	16,931	21,012
Gross profit	4,572	8,558
Operating expenses:
Sales and marketing	1,993	3,389
General and administrative	3,416	3,186
Research and development	1,201	965
Total operating expenses	6,610	7,540
Operating (loss) income	(2,038)	1,018
Interest income, net	184	215
Other expense, net	(107)	(134)
(Loss) income from continuing operations before income taxes, non-controlling interest and discontinued operations	(1,961)	1,099
Income tax expense	18	131
(Loss) income from continuing operations before non-controlling interest and discontinued operations	(1,979)	968
Loss from discontinued operations (Note 3)		(193)
Net (loss) income	$ (1,979)	$ 775
Basic (loss) income per share:
Continuing operations	$ (0.22)	$ 0.11
Discontinued operations		(0.02)
Net (loss) income per share:	(0.22)	0.09
Diluted (loss) income per share:
Continuing operations	(0.22)	0.10
Discontinued operations		(0.02)
Net (loss) income per share:	$ (0.22)	$ 0.08
Average shares outstanding:
Basic	8,813	8,705
Diluted	8,813	9,382

Consolidated Condensed Statem_2

Consolidated Condensed Statements Of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Consolidated Statements Of Comprehensive Income (Loss) [Abstract]
Net (loss) income	$ (1,979)	$ 775
Foreign currency translation adjustment, net of taxes of $0	13	7
Pension and postretirement obligations, net of taxes of $0	5	5
Investment in partnerships, net of taxes of $0		118
Comprehensive (loss) income	$ (1,961)	$ 905

Consolidated Condensed Statem_3

Consolidated Condensed Statements Of Comprehensive (Loss) Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Consolidated Statements Of Comprehensive Income (Loss) [Abstract]
Foreign currency translation adjustment, tax	$ 0	$ 0
Pension and postretirement obligations, tax	0	0
Investment in partnerships, tax	$ 0	$ 0

Consolidated Condensed Statem_4

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net (loss) income	$ (1,979)	$ 775
Loss from discontinued operations		193
(Loss) income from continuing operations	(1,979)	968
Adjustments to reconcile net (loss) income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	921	797
Equity in loss of partnerships	45	65
Stock-based compensation	376	329
Change in allowance for doubtful accounts	6	(439)
Changes in operating assets and liabilities:
Accounts receivable	746	1,438
Inventories	(2,738)	(220)
Contract assets	158	(696)
Other assets	488	877
Accounts payable	327	(983)
Accrued expenses	340	(1,453)
Other liabilities	71	29
Net cash (used in) provided by operating activities of continuing operations	(1,239)	712
Net cash provided by (used in) operating activities of discontinued operations	3	(277)
Net cash (used in) provided by operating activities	(1,236)	435
Cash flows from investing activities:
Purchases of machinery and equipment	(1,678)	(938)
Payments for acquisition of other assets	(91)	(586)
Purchase of investment securities	(76)	(34,516)
Proceeds from sale of investment securities		38,015
Proceeds from maturities of investment securities	9,850	3,464
Investment in partnerships		(568)
Net cash provided by investing activities of continuing operations	8,005	4,871
Net cash used in investing activities of discontinued operations		(16)
Net cash provided by investing activities	8,005	4,855
Cash flows from financing activities:
Payment of financing leases	(28)	(32)
Exercise of stock options and employee stock purchase plan shares	68	88
Withholding of common stock upon vesting of restricted stock units	(198)	(235)
Net cash (used in) financing activities	(158)	(179)
Effect of exchange rate changes on cash	20	32
Net increase in cash	6,631	5,143
Cash, cash equivalents and restricted cash, beginning of period	9,162	8,047
Cash, cash equivalents and restricted cash, end of period	15,793	13,190
Non-cash investing and financing:
Acquisition of machinery and equipment in accounts payable	$ 187	160
Fitting software other asset through liabilities incurred and exchange of investment in partnership		$ 3,093

Consolidated Condensed Statem_5

Consolidated Condensed Statements Of Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 8,664	$ 84,999	$ (509)	$ (927)	$ (253)	$ 91,974
Balance, shares at Dec. 31, 2018	8,664
Exercise of stock options, net	$ 27	(9)				18
Exercise of stock options, net, shares	27
Withholding of common stock upon vesting of restricted stock units	$ 20	(255)				(235)
Withholding of common stock upon vesting of restricted stock units, shares	20
Shares issued under the employee stock purchase plan	$ 3	67				70
Shares issued under the employee stock purchase plan, shares	3
Stock-based compensation		329				329
Net (loss) income			775			775
Comprehensive income				130		130
Balance at Mar. 31, 2019	$ 8,714	85,131	266	(797)	(253)	93,061
Balance, shares at Mar. 31, 2019	8,714
Balance at Dec. 31, 2019	$ 8,781	86,770	(4,286)	(520)	(253)	90,492
Balance, shares at Dec. 31, 2019	8,781
Exercise of stock options, net	$ 11	4				$ 15
Exercise of stock options, net, shares	11					48
Withholding of common stock upon vesting of restricted stock units	$ 22	(220)				$ (198)
Withholding of common stock upon vesting of restricted stock units, shares	22
Shares issued under the employee stock purchase plan	$ 5	48				53
Shares issued under the employee stock purchase plan, shares	5
Stock-based compensation		376				376
Net (loss) income			(1,979)			(1,979)
Comprehensive income				18		18
Balance at Mar. 31, 2020	$ 8,819	$ 86,978	$ (6,265)	$ (502)	$ (253)	$ 88,777
Balance, shares at Mar. 31, 2020	8,819

General

General	3 Months Ended
General	Mar. 31, 2020
General [Abstract]
General	1. General In the opinion of management, the accompanying consolidated condensed financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly IntriCon Corporation's (“IntriCon” or the “Company”) consolidated condensed financial position as of March 31, 2020 and December 31, 2019, and the consolidated condensed results of its operations, statements of equity and cash flows for the three months ended March 31, 2020 and 2019. Results of operations for the interim periods are not necessarily indicative of the results of operations expected for the full year or any other interim period. The preparation of consolidated condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates particularly as it relates to estimates reliant on forecasts and other assumptions impacted by the COVID-19 pandemic . In March 2020, the World Health Organization categorized COVID-19 (coronavirus) as a pandemic and the President of the United States declared the outbreak a national emergency. The Company considered the impacts of COVID-19 on the assumptions and estimates used, including reviewing our long-lived assets for impairment, and determined that for the three months ended March 31, 2020, COVID-19 did not have a material adverse impact . These consolidated condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2019 Annual Report on Form 10-K filed with the SEC. On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its United Kingdom (UK) subsidiary within our body worn device segment. For all periods presented, the Company classified this business as discontinued operations, and accordingly, has reclassified historical financial data presented herein. See Note 3. The consolidated condensed financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
New Accounting Pronouncements	Mar. 31, 2020
New Accounting Pronouncements [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses Topic 326 , which requires certain financial assets to be measured at amortized cost net of an allowance for estimated credit losses, such that the net receivable represents the present value of expected cash collection. In addition, this standard update requires that certain financial assets be measured at amortized cost reflecting an allowance for estimated credit losses expected to occur over the life of the assets. The estimate of credit losses must be based on all relevant information including historical information, current conditions, and reasonable and supportable forecasts that affect the collectability of the amounts. Topic 326 is effective for interim and annual periods beginning January 1, 2022 for smaller reporting companies. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes as part of its overall simplification initiative to reduce costs and complexity in applying accounting standards while maintaining or improving the usefulness of the information provided to users of the financial statements. Amendments include removal of certain exceptions to the general principals of ASC 740, Income Taxes , and simplification in several other areas such as accounting for franchise tax (or similar tax) that is partially based on income. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 , which clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under ASC 323, Investments – Equity Method and Joint Venture , for the purposes of applying the measurement alternative in accordance with ASC 321, Investments – Equity Securities , immediately before applying or upon discontinuing the equity method. ASU 2020-01 is effective for interim and annual periods beginning after December 15, 2020. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In April 2020, the FASB issued ASU 2020-04, Reference Rate Reform Topic 848 , which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. Topic 848 provides optional expedients and exceptions for applying U.S. GAAP to transactions affected by reference rate reform if certain criteria are met. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows.

Discontinued Operations

Discontinued Operations	3 Months Ended
Discontinued Operations	Mar. 31, 2020
Discontinued Operations [Abstract]
Discontinued Operations	3. Discontinued Operations On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its UK subsidiary within the body worn device segment. Prior to March 31 , 2020 , the remaining assets and liabilities of the subsidiary were settled . As the disposal meets the definition of a strategic shift in accordance with ASC 205, the results of the UK operations have been classified as loss from discontinued operations, in the accompanying consolidated condensed statements of operations, comprehensive (loss) income and cash flows . Current assets and liabilities of the discontinued operations have been reclassified and reflected on the accompanying consolidated condensed balance sheets as “Current assets of discontinued operations,” and “Liabilities of discontinued operations”, respectively. Prior periods relating to our discontinued operations have been reclassified to reflect consistency within our consolidated condensed financial statements. There was no income tax expense or benefit related to our discontinued operations for any period presented. The total assets and liabilities of the UK subsidiary at December 31, 2019 were as follows: December 31, 2019 Other current assets $ 80 Other accrued liabilities 77 Net assets (liabilities) $ 3 The following table shows the results of the UK subsidiary’s discontinued operations: Three Months Ended March 31, 2019 Revenue, net $ 539 Cost of goods sold 346 Gross profit 193 Sales and marketing 147 General and administrative 239 Total operating expenses 386 Loss from discontinued operations $ (193)

Segment Reporting

Segment Reporting	3 Months Ended
Segment Reporting	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	4. Segment Reporting The Company currently operates in two reportable segments: body-worn devices and hearing health direct-to-end-consumer (DTEC). The nature of distribution and services has been deemed separately identifiable. Therefore, segment reporting has been applied. The following table summarizes certain data from continuing operations by reportable segment: For the Three Months Ended March 31, 2020 Body Worn Devices Hearing Health DTEC Total Revenue, net $ 20,330 $ 1,173 $ 21,503 Loss from continuing operations before income taxes and discontinued operations (1,078) (883) (1,961) Depreciation and amortization 895 26 921 Capital expenditures 1,678 - 1,678 For the Three Months Ended March 31, 2019 Body Worn Devices Hearing Health DTEC Total Revenue, net $ 27,940 $ 1,630 $ 29,570 Income (loss) from continuing operations before income taxes and discontinued operations 2,581 (1,482) 1,099 Depreciation and amortization 736 61 797 Capital expenditures 918 20 938 The following table summarizes the identifiable assets (excluding goodwill) and goodwill by reportable segment as of the following dates: March 31, December 31, 2020 2019 Body Worn Devices: Identifiable assets (excluding goodwill) $ 99,802 $ 101,311 Goodwill 9,551 9,551 Hearing Health DTEC: Identifiable assets (excluding goodwill) 2,365 2,651

Geographic Information

Geographic Information	3 Months Ended
Geographic Information	Mar. 31, 2020
Segment Reporting [Abstract]
Geographic Information	5. Geographic Information The geographical distribution of long-lived assets to geographical areas consisted of the following at: March 31, December 31, 2020 2019 United States $ 13,421 $ 12,215 Singapore 1,247 1,263 Other 63 73 Consolidated $ 14,731 $ 13,551 Long-lived assets consist of machinery and equipment. Excluded from long-lived assets are investments in partnerships, patents, goodwill, operating lease right-of-use (ROU) assets and certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets. The geographical distribution of net revenue to geographical areas for the three months ended March 31, 2020 and 2019 were as follows: Three Months Ended Net Revenue to Geographical Areas March 31, 2020 March 31, 2019 United States $ 17,788 $ 24,215 Europe 1,187 1,664 Asia 2,200 3,509 All other countries 328 182 Consolidated $ 21,503 $ 29,570 Geographic net revenue is allocated based on the location of the customer. For the three months ended March 31, 2020 , and 2019, one customer accounted for 63% and 58% , respectively, of the Company’s consolidated net revenue. Two customers combined accounted for 54% and 51% of the Company’s consolidated accounts receivable at March 31, 2020 and December 31, 2019, respectively. One customer accounted for 91% and 86% of the Company’s consolidated contract assets at March 31 , 2020 and December 31, 2019 , respectively.

Investment In Partnerships

Investment In Partnerships	3 Months Ended
Investment In Partnerships	Mar. 31, 2020
Investment In Partnerships [Abstract]
Investment In Partnerships	6. Investment in Partnerships Investment in partnerships consisted of the following: March 31, December 31, 2020 2019 Investment in Signison $ 473 $ 852 Other 277 308 Total $ 750 $ 1,160 The Company has a 50% ownership interest in Signison as of March 31, 2020. Signison is accounted for in the Company’s consolidated financial statements using the equity method.

Investment Securities

Investment Securities	3 Months Ended
Investment Securities	Mar. 31, 2020
Investments Securities [Abstract]
Investment Securities	7. Investment Securities T he Company invests in commercial paper, corporate notes and bonds with original maturities of less than two years. The Company classifies these investments as held to maturity based on our intent and ability to hold these investments until maturity. As a result, these investments are recorded at amortized cost, which approximates fair value, using level 1 inputs. The maturity dates of our investments as of March 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 1,897 $ - $ 1,897 Corporate Notes and Bonds 14,992 5,379 20,371 Total Investments $ 16,889 $ 5,379 $ 22,268 The maturity dates of our investments as of December 31, 2019 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 8,461 $ - $ 8,461 Corporate Notes and Bonds 14,990 8,629 23,619 Total Investments $ 23,451 $ 8,629 $ 32,080 T he Company also maintains excess funds within level 2 money market accounts included within cash and cash equivalents. Cash available in our money market accounts at March 31, 2020 and December 31, 2019 was $14,821 and $7,200 , respectively.

Inventories

Inventories	3 Months Ended
Inventories	Mar. 31, 2020
Inventories [Abstract]
Inventories	8. Inventories Inventories consisted of the following at: Raw materials Work-in process Finished products and components Total March 31, 2020 Domestic $ 11,341 $ 3,501 $ 1,160 $ 16,002 Foreign 2,583 341 189 3,113 Total $ 13,924 $ 3,842 $ 1,349 $ 19,115 December 31, 2019 Domestic $ 10,379 $ 736 $ 2,375 $ 13,490 Foreign 2,482 215 190 2,887 Total $ 12,861 $ 951 $ 2,565 $ 16,377

Other Assets, Net

Other Assets, Net	3 Months Ended
Other Assets, Net	Mar. 31, 2020
Other Assets, Net [Abstract]
Other Assets, Net	9. Other Assets, Net Other assets, net consisted of the following at: March 31, December 31, 2020 2019 Self-fitting software $ 3,679 $ 3,679 Technology access 1,768 1,866 Other 455 510 Total $ 5,902 $ 6,055 The estimated useful life for the self-fitting software and technology access is 5 - 7 years. The self-fitting software is expected to begin amortizing in the second quarter of 2020. Accumulated amortization for the technology access asset is $982 and $884 as of March 31, 2020 and December 31, 2019, respectively. In January 2019, the Company purchased the source code for self-fitting software from Soundperience for 1,750 Euros and also transferred our 49% ownership interest in Soundperience to the majority owner. The Company has capitalized the self-fitting software within other assets, net based on the cost of the consideration transferred and will begin amortizing the asset when it is placed into service. Included in the capitalized cost of the self-fitting software is $586 of cash paid at closing as well as non-cash amounts of $869 due in future quarterly installments over the next four years, $533 due in January 2023 and $1,691 for the value of the partnership and license agreement transferred. The future payments are due in Euros and the related liabilities will be revalued based on exchange rates as of each reporting period. As of March 31, 20 20 , outstanding liabilities consist of $238 other accrued current liabilities and $857 other long-term liabilities.

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
Other Accrued Liabilities	Mar. 31, 2020
Other Accrued Liabilities [Abstract]
Other Accrued Liabilities	10. Other Accrued Liabilities Other accrued liabilities consisted of the following at: March 31, 2020 December 31, 2019 Pension $ 120 $ 120 Postretirement benefit obligation 71 71 Deferred revenue 327 327 Self-fitting software liability 238 285 Technology access liability 989 1,236 Other 729 830 Total $ 2,474 $ 2,869 Technology access liabilities are due in equal quarterly installments through January 2022.

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2020
Leases [Abstract]
Leases	11. Leases The Company’s leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more. The Company has three leased facilities in Minnesota, two that expire in 2022 and one that expires in 2023, one leased facility in Illinois that expires in 2022, one leased facility in Singapore that expires in 2020, one leased facility in Indonesia that expires in 2024, and one leased facility in Germany that expires in 2022. Certain foreign leases allow for variable lease payments that depend on an index or a market rate adjustment for the respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in profit and loss. The facility leases include options to extend for terms ranging from one to five years . Lease options that the Company is reasonably certain to execute, are included in the determination of the ROU asset and lease liability. Our Indonesia lease includes embedded forward starting leases that will begin in 2022 and 2024 for additional square footage, which will result in the recognition of an additional ROU asset and lease liability in those periods of approximately $103 and $72 , respectively. The Company also leases equipment that include bargain purchase options at termination. These leases have been classified as finance leases. As of March 31, 2020, the Company has a weighted-average lease term of 1.2 years for its finance leases, and 2.9 years for its operating leases. As of March 31, 2020, the Company has a weighted-average discount rate of 5.56% for its finance leases, and 5.26% for its operating leases. Discount rates are determined based on 5 year term incremental borrowing rates at inception of the lease. Operating cash flows for the three months ended March 31, 2020 from operating leases were $507 . Financing lease assets are classified as machinery and equipment within the consolidated balance sheet. The following tables summarizes lease costs by type: Three Months Ended March 31, 2020 March 31, 2019 Lease cost Finance lease cost: Amortization of right-of-use assets $ 26 $ 25 Interest on lease liabilities 2 3 Operating lease cost 481 460 Variable lease cost* 151 138 Total lease cost $ 660 $ 626 *Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our domestic and foreign building leases. Maturities of lease liabilities are as follows as of March 31, 2020: Operating Leases Financing Leases Total 2020 $ 1,375 $ 73 $ 1,448 2021 1,567 31 1,598 2022 1,003 3 1,006 2023 396 - 396 2024 80 - 80 2025 and thereafter - - - Total lease payments 4,421 107 4,528 Less: Interest (313) (4) (317) Present value of lease liabilities $ 4,108 $ 103 $ 4,211

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	12. Income Taxes Income tax expense for the three months ended March 31, 2020 was $18 compared to $131 for the same period in 2019. The expense was largely due to our foreign operations. The Company has net operating loss carryforwards for U.S. federal income tax purposes. The Company has recorded a full valuation allowance against the deferred tax asset as of March 31, 2020. The following was the (loss) income from continuing operations before income taxes and discontinued operations for each jurisdiction in which the Company has operations for the three months ended March 31, 2020 and 2019. Three Months Ended March 31, 2020 March 31, 2019 United States $ (1,842) $ 885 Singapore (153) 117 Indonesia 18 21 Germany 16 76 (Loss) income from continuing operations before income taxes and discontinued operations $ (1,961) $ 1,099 CARES Act On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which contained in part, an allowance for deferral of the employer portion of Social Security employment tax liabilities until 2021 and 2022, as well as a COVID-19 employee retention tax credit (“CRC”) of up to $5,000 per eligible employee. Based on the timing of the CARES Act, for the three months ended March 31, 2020, the related tax benefits from the CARES Act were not material. We are currently reviewing the potential future benefits related to employee retention tax credits and the payroll tax deferral provision to assess the impact on our financial position, results of operations and cash flows.

Shareholders' Equity And Stock-

Shareholders' Equity And Stock-Based Compensation	3 Months Ended
Shareholders' Equity And Stock-Based Compensation	Mar. 31, 2020
Common Stock And Stock Options [Abstract]
Shareholders' Equity And Stock-Based Compensation	13. Shareholders’ Equity and Stock-based Compensation The Company has a 2006 Equity Incentive Plan and a 2015 Equity Incentive Plan. The 2015 Equity Incentive Plan replaced the 2006 Equity Incentive Plan and new grants may not be made under the 2006 Plan. Under the 2015 Equity Incentive Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”) and other equity-based awards. Under all awards, the terms are fixed on the grant date. For the three months ended March 31, 2020, t he Company granted 66 RSUs with a weighted average closing price on the date of grant of $17.48 . The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units. The Company has also granted stock options under the plans. Options granted under the plans generally vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant and have a maximum term of 10 years. Stock award activity as of and during the three months ended March 31, 2020 was as follows: Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2019 746 128 874 $ 6.39 Awards granted - 66 66 - Awards exercised or released (15) (33) (48) 4.72 Outstanding at March 31, 2020 731 161 892 $ 6.43 $ 5,802 Exercisable at March 31, 2020 695 - 695 $ 6.37 $ 3,751 Available for future grant at December 31, 2019 183 Available for future grant at March 31, 2020 131 (a) The weighted average exercise price calculation does not include outstanding RSUs The number of shares available for future grants at March 31, 2020 does not include a total of up to 357 shares subject to options outstanding under the 2006 Equity Incentive Plan, which will become available for grant under the 2015 Equity Incentive Plan as outstanding options under the 2006 Equity Incentive Plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise of such options. The Company recorded $376 and $329 of non-cash stock compensation expense for the three months ended March 31, 2020 and 2019, respectively. As of March 31 , 2020 , there was $2,730 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 2.13 years. The total intrinsic value of options exercised during the three months ended March 31 , 2020 was $189 . The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through March 31, 2020, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 5 and 3 shares purchased under the plan for the three months ended March 31, 2020 and 2019, respectively.

Income Per Share

Income Per Share	3 Months Ended
Income Per Share	Mar. 31, 2020
Income Per Share [Abstract]
Income Per Share	14. Income Per Share The following table presents a reconciliation between basic and diluted earnings per share: Three Months Ended March 31, 2020 March 31, 2019 Numerator: (Loss) income from continuing operations before discontinued operations $ (1,979) $ 968 Loss from discontinued operations (Note 3) - (193) Net (loss) income $ (1,979) $ 775 Denominator: Basic – weighted shares outstanding 8,813 8,705 Weighted shares assumed upon exercise of stock awards - 677 Diluted – weighted shares outstanding 8,813 9,382 Basic (loss) income per share attributable to IntriCon shareholders: Continuing operations $ (0.22) $ 0.11 Discontinued operations - (0.02) Net (loss) income per share: $ (0.22) $ 0.09 Diluted (loss) income per share attributable to IntriCon shareholders: Continuing operations $ (0.22) $ 0.10 Discontinued operations - (0.02) Net (loss) income per share: $ (0.22) $ 0.08 The dilutive impact summarized above relates to the periods when the average market price of Company stock exceeded the exercise price of the potentially dilutive options. Earnings per common share was based on the weighted average number of common shares outstanding during the periods when computing the basic earnings per share. When dilutive, stock options are included as equivalents using the treasury stock method when computing the diluted earnings per share. Shares represented by RSUs are also included in the dilution calculation. For the three months ended March 31 , 2020 , weighted average options and RSU’s outstanding of 893 were excluded from the dilutive calculation as their effect would have been antidilutive based on losses in the period. No options or RSUs were excluded from the dilutive calculation for the three months ended March 31, 2019.

Legal Proceedings

Legal Proceedings	3 Months Ended
Legal Proceedings	Mar. 31, 2020
Contingencies And Commitments [Abstract]
Legal Proceedings	15. Legal Proceedings The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or advised the Company that they need to investigate further. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, many of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company's consolidated financial position or results of operations. The Company is also involved in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect our consolidated financial position, liquidity or results of operations.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
Related-Party Transactions	Mar. 31, 2020
Related-Party Transactions [Abstract]
Related-Party Transactions	16. Related-Party Transactions The Company has a 50% ownership in Signison, a German based hearing health company. Signison owes the Company a notes receivable , net of allowances, of $473 which is included in investment in partnership on the balance sheet as of March 31, 20 20 .

Revenue, Net

Revenue, Net	3 Months Ended
Revenue, Net	Mar. 31, 2020
Revenue, Net [Abstract]
Revenue, Net	17. Revenue, Net Medical market revenue recognition- Customer orders from the medical market consist of a specified number of assembled and customized parts that the customer further integrates into their production process to produce market ready products. Customer orders do not include additional follow-on goods or services. Each order is for a series of distinct units that comprise a single performance obligation. With the exception of prompt payment discounts, the transaction price for medical market products is the invoiced amount. Variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price are not present. All of the Company’s products manufactured for the medical market are designed to each customer’s specifications, do not have an alternative use and cannot be sold or redirected by the Company to others. The Company considers contractual arrangements, laws and legal precedent in determining enforceable right. The Company has an enforceable right to payment for any finished or in-process units, including a reasonable margin, if the customer terminates the contract for reasons other than the Company’s failure to perform as promised within our medical diabetes market and a select customer within our other medical market. For contractual arrangements in which an enforceable right exists, control of these units is deemed to transfer to the customer over time during the manufacturing process, using the same measure of progress toward satisfying the promise to deliver the units to the customer. Consequently, the transaction price is recognized as revenue over time for contractual arrangements with an enforceable right, based on actual costs incurred in the manufacturing process to date relative to total expected costs to produce all ordered units. The transaction price for contractual arrangements without an enforceable right to payment for any finished or in-process units including a reasonable margin is recognized as revenue at a point in time. Medical market products are invoiced when shipped and paid within normal commercial terms. The Company records a contract asset for revenue recognized over time in the production process for customized products that have not been shipped or invoiced to the customer. The following tables set forth, for the periods indicated, timing of revenue recognition by market: Timing of revenue recognition for the three months ended March 31, 2020: Products and services transferred at point in time Products and services transferred over time Total Medical: Diabetes $ - $ 13,530 $ 13,530 Other Medical (a) 1,820 1,008 2,828 Hearing Health: Value Based DTEC 1,173 - 1,173 Value Based ITEC 744 - 744 Legacy OEM 1,964 - 1,964 Professional Audio Communications: 1,264 - 1,264 Total Revenue, net $ 6,965 $ 14,538 $ 21,503 (a) During the quarter ended March 31, 2020, we recorded a cumulative adjustment of $1.2 million to reduce revenue within our other medical market to correct an error related to prior periods as a result of our determination that a portion of our sales being recognized over time needed to be recognized at a point in time. The adjustment included a reduction of the related cost of goods sold of $0.8 million and related impacts to reduce the contract asset and an increase to inventory. The adjustment was not material to our Consolidated Financial Statements for any quarterly or annual period. Timing of revenue recognition for the three months ended March 31, 2019: Products and services transferred at point in time Products and services transferred over time Total Medical: Diabetes $ - $ 17,164 $ 17,164 Other Medical - 3,629 3,629 Hearing Health: Value Based DTEC 1,630 - 1,630 Value Based ITEC 2,577 - 2,577 Legacy OEM 2,803 - 2,803 Professional Audio Communications: 1,767 - 1,767 Total Revenue, net $ 8,777 $ 20,793 $ 29,570

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Amendment to Credit Facility On May 13, 2020, the Company and its domestic subsidiaries entered into a Fourteenth Amendment to Loan and Security Agreement and Waiver (the “Fourteenth Amendment”) with CIBC Bank USA. The Fourteenth Amendment, among other things: · Increased the Company’s revolving loan borrowing capacity to $12.0 million from its then current capacity of $7.0 million; · Added provisions addressing interest rates following the unavailability of the London Interbank Offered Rate or LIBOR; · Waived a default in the fixed charge coverage ratio covenant as of March 31, 2020; · Eliminated the funded debt to EBITDA ratio and fixed charge coverage ratio for the quarter ending June 30, 2020; · Added a financial covenant requiring that at all times until September 30, 2020, the borrowers maintain at least $ 15.0 million of liquidity, calculated as the sum of (a) cash on hand, plus (b) cash equivalent investments, plus (c) available borrowing capacity under the revolving credit facility. After giving effect to the waiver in the Fourteenth Amendment, the Company was in compliance with all applicable covenants under the credit facility as of March 31, 2020. Strategic Restructuring Plan On May 15, 2020, the management of the Company committed the Company to, and began executing on, a strategic restructuring plan designed to accelerate the Company’s future growth by focusing resources on the highest potential growth areas. The plan, which was supported by the Company’s Board of Directors, is expected to be completed by the end of the 2020 second quarter. Following the Company’s decision last quarter to no longer pursue a direct-to-end-consumer approach to the hearing health market, we recently made the decision to transition our remaining direct-to-end-consumer operations at Hearing Help Express to solely support our partnership initiatives. In addition, while continued uncertainties remain from the COVID-19 pandemic, we are taking many significant steps to decrease our expenditure profile and current spending run-rate. The following are significant items included in our strategic restructuring plan: · We completed a global net workforce reduction of approximately 35 positions, including many of the previously furloughed positions, resulting in an annual cost savings of approximately $2.4 million · We changed our focus to seeking partners in the hearing health market, resulting in approximately $2.0 million reduction in Hearing Help Express consumer advertising expense in 2020 as compared to 2019 · In connection with the strategic restructuring plan, we anticipate incurring a $1.2 million to $1.5 million restructuring charge during the second quarter ending June 30, 2020 related to one-time employee termination costs, asset impairment charges and other operations-related expenses. Acquisition of Emerald Medical Services On May 18, 2020, IntriCon Pte. Ltd. (“Buyer”), a wholly-owned subsidiary of the Company, acquired all of the outstanding shares of Emerald Medical Services Pte., Ltd., a Singapore company (“Emerald”), pursuant to a Share Purchase Agreement dated the same date among Buyer, Emerald and the direct and indirect owners of Emerald. Emerald, based in Singapore, is a provider of joint development medical device manufacturing services for complex catheter applications. The Share Purchase Agreement provides for a purchase price consisting of: · a cash payment paid at closing of $7,128 , subject to a post-closing working capital adjustment; · 80 thousand shares of the Company’s common stock issued at closing, which shares will be held in an escrow account for a period of 18 months to resolve any post-closing claims by the Buyer; · a cash payment of $500 payable in the event that regulatory approval in Japan is obtained for a particular product within twelve months of closing; · an earn-out payment of between $333 and $1,000 if Emerald has net revenues ranging from $9,000 to $11,000 during the first year after closing; and · additional earn-out payments equal to 28% of net revenues arising from the sale of certain products or to certain customers for each of the first three years after closing . The cash portion of the purchase was paid from Company internal funds. COVID-19 Pandemic There are many uncertainties regarding the COVID-19 pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. We are unable to predict the impact that COVID-19 will have on our financial position and operating results due to numerous uncertainties. The Company expects to continue to assess the evolving impact of COVID-19 and intends to make adjustments to its responses accordingly.

New Accounting Pronouncements (

New Accounting Pronouncements (Policy)	3 Months Ended
New Accounting Pronouncements (Policy)	Mar. 31, 2020
New Accounting Pronouncements [Abstract]
New Accounting Pronouncements	In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses Topic 326 , which requires certain financial assets to be measured at amortized cost net of an allowance for estimated credit losses, such that the net receivable represents the present value of expected cash collection. In addition, this standard update requires that certain financial assets be measured at amortized cost reflecting an allowance for estimated credit losses expected to occur over the life of the assets. The estimate of credit losses must be based on all relevant information including historical information, current conditions, and reasonable and supportable forecasts that affect the collectability of the amounts. Topic 326 is effective for interim and annual periods beginning January 1, 2022 for smaller reporting companies. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes as part of its overall simplification initiative to reduce costs and complexity in applying accounting standards while maintaining or improving the usefulness of the information provided to users of the financial statements. Amendments include removal of certain exceptions to the general principals of ASC 740, Income Taxes , and simplification in several other areas such as accounting for franchise tax (or similar tax) that is partially based on income. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 , which clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under ASC 323, Investments – Equity Method and Joint Venture , for the purposes of applying the measurement alternative in accordance with ASC 321, Investments – Equity Securities , immediately before applying or upon discontinuing the equity method. ASU 2020-01 is effective for interim and annual periods beginning after December 15, 2020. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows. In April 2020, the FASB issued ASU 2020-04, Reference Rate Reform Topic 848 , which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. Topic 848 provides optional expedients and exceptions for applying U.S. GAAP to transactions affected by reference rate reform if certain criteria are met. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
Discontinued Operations (Tables)	Mar. 31, 2020
Discontinued Operations [Abstract]
Schedule Of Discontinued Operations Balance Sheet	December 31, 2019 Other current assets $ 80 Other accrued liabilities 77 Net assets (liabilities) $ 3
Summary Of Results Of Discontinued Operations	Three Months Ended March 31, 2019 Revenue, net $ 539 Cost of goods sold 346 Gross profit 193 Sales and marketing 147 General and administrative 239 Total operating expenses 386 Loss from discontinued operations $ (193)

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
Segment Reporting (Tables)	Mar. 31, 2020
Segment Reporting [Abstract]
Summary Of Data By Industry Segment	For the Three Months Ended March 31, 2020 Body Worn Devices Hearing Health DTEC Total Revenue, net $ 20,330 $ 1,173 $ 21,503 Loss from continuing operations before income taxes and discontinued operations (1,078) (883) (1,961) Depreciation and amortization 895 26 921 Capital expenditures 1,678 - 1,678 For the Three Months Ended March 31, 2019 Body Worn Devices Hearing Health DTEC Total Revenue, net $ 27,940 $ 1,630 $ 29,570 Income (loss) from continuing operations before income taxes and discontinued operations 2,581 (1,482) 1,099 Depreciation and amortization 736 61 797 Capital expenditures 918 20 938 The following table summarizes the identifiable assets (excluding goodwill) and goodwill by reportable segment as of the following dates: March 31, December 31, 2020 2019 Body Worn Devices: Identifiable assets (excluding goodwill) $ 99,802 $ 101,311 Goodwill 9,551 9,551 Hearing Health DTEC: Identifiable assets (excluding goodwill) 2,365 2,651

Geographic Information (Tables)

Geographic Information (Tables)	3 Months Ended
Geographic Information (Tables)	Mar. 31, 2020
Segment Reporting [Abstract]
Geographical Distribution Of Long-Lived Assets, Net	March 31, December 31, 2020 2019 United States $ 13,421 $ 12,215 Singapore 1,247 1,263 Other 63 73 Consolidated $ 14,731 $ 13,551
Geographical Distribution Of Net Sales	Three Months Ended Net Revenue to Geographical Areas March 31, 2020 March 31, 2019 United States $ 17,788 $ 24,215 Europe 1,187 1,664 Asia 2,200 3,509 All other countries 328 182 Consolidated $ 21,503 $ 29,570

Investment In Partnerships (Tab

Investment In Partnerships (Tables)	3 Months Ended
Investment In Partnerships (Tables)	Mar. 31, 2020
Investment In Partnerships [Abstract]
Investments in Partnerships	March 31, December 31, 2020 2019 Investment in Signison $ 473 $ 852 Other 277 308 Total $ 750 $ 1,160

Investment Securities (Tables)

Investment Securities (Tables)	3 Months Ended
Investment Securities (Tables)	Mar. 31, 2020
Investments Securities [Abstract]
Summary Of Maturity Dates Of Investments	The maturity dates of our investments as of March 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 1,897 $ - $ 1,897 Corporate Notes and Bonds 14,992 5,379 20,371 Total Investments $ 16,889 $ 5,379 $ 22,268 The maturity dates of our investments as of December 31, 2019 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 8,461 $ - $ 8,461 Corporate Notes and Bonds 14,990 8,629 23,619 Total Investments $ 23,451 $ 8,629 $ 32,080

Inventories (Tables)

Inventories (Tables)	3 Months Ended
Inventories (Tables)	Mar. 31, 2020
Inventories [Abstract]
Schedule Of Inventories	Raw materials Work-in process Finished products and components Total March 31, 2020 Domestic $ 11,341 $ 3,501 $ 1,160 $ 16,002 Foreign 2,583 341 189 3,113 Total $ 13,924 $ 3,842 $ 1,349 $ 19,115 December 31, 2019 Domestic $ 10,379 $ 736 $ 2,375 $ 13,490 Foreign 2,482 215 190 2,887 Total $ 12,861 $ 951 $ 2,565 $ 16,377

Other Assets, Net (Tables)

Other Assets, Net (Tables)	3 Months Ended
Other Assets, Net (Tables)	Mar. 31, 2020
Other Assets, Net [Abstract]
Schedule Of Other Assets, Net	March 31, December 31, 2020 2019 Self-fitting software $ 3,679 $ 3,679 Technology access 1,768 1,866 Other 455 510 Total $ 5,902 $ 6,055

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
Other Accrued Liabilities (Tables)	Mar. 31, 2020
Other Accrued Liabilities [Abstract]
Components Of Other Accrued Liabilities	March 31, 2020 December 31, 2019 Pension $ 120 $ 120 Postretirement benefit obligation 71 71 Deferred revenue 327 327 Self-fitting software liability 238 285 Technology access liability 989 1,236 Other 729 830 Total $ 2,474 $ 2,869

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2020
Leases [Abstract]
Summary Of Lease Costs By Type	Three Months Ended March 31, 2020 March 31, 2019 Lease cost Finance lease cost: Amortization of right-of-use assets $ 26 $ 25 Interest on lease liabilities 2 3 Operating lease cost 481 460 Variable lease cost* 151 138 Total lease cost $ 660 $ 626 *Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our domestic and foreign building leases.
Maturities Of Lease Liabilities	Operating Leases Financing Leases Total 2020 $ 1,375 $ 73 $ 1,448 2021 1,567 31 1,598 2022 1,003 3 1,006 2023 396 - 396 2024 80 - 80 2025 and thereafter - - - Total lease payments 4,421 107 4,528 Less: Interest (313) (4) (317) Present value of lease liabilities $ 4,108 $ 103 $ 4,211

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
Income Taxes (Tables)	Mar. 31, 2020
Income Taxes [Abstract]
Domestic And Foreign Income Taxes (Benefits)	Three Months Ended March 31, 2020 March 31, 2019 United States $ (1,842) $ 885 Singapore (153) 117 Indonesia 18 21 Germany 16 76 (Loss) income from continuing operations before income taxes and discontinued operations $ (1,961) $ 1,099

Shareholders' Equity And Stoc_2

Shareholders' Equity And Stock-Based Compensation (Tables)	3 Months Ended
Shareholders' Equity And Stock-Based Compensation (Tables)	Mar. 31, 2020
Common Stock And Stock Options [Abstract]
Summary Of Stock Option Activity	Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2019 746 128 874 $ 6.39 Awards granted - 66 66 - Awards exercised or released (15) (33) (48) 4.72 Outstanding at March 31, 2020 731 161 892 $ 6.43 $ 5,802 Exercisable at March 31, 2020 695 - 695 $ 6.37 $ 3,751 Available for future grant at December 31, 2019 183 Available for future grant at March 31, 2020 131 (a) The weighted average exercise price calculation does not include outstanding RSUs

Income Per Share (Tables)

Income Per Share (Tables)	3 Months Ended
Income Per Share (Tables)	Mar. 31, 2020
Income Per Share [Abstract]
Reconciliation Between Basic And Diluted Earnings Per Share	Three Months Ended March 31, 2020 March 31, 2019 Numerator: (Loss) income from continuing operations before discontinued operations $ (1,979) $ 968 Loss from discontinued operations (Note 3) - (193) Net (loss) income $ (1,979) $ 775 Denominator: Basic – weighted shares outstanding 8,813 8,705 Weighted shares assumed upon exercise of stock awards - 677 Diluted – weighted shares outstanding 8,813 9,382 Basic (loss) income per share attributable to IntriCon shareholders: Continuing operations $ (0.22) $ 0.11 Discontinued operations - (0.02) Net (loss) income per share: $ (0.22) $ 0.09 Diluted (loss) income per share attributable to IntriCon shareholders: Continuing operations $ (0.22) $ 0.10 Discontinued operations - (0.02) Net (loss) income per share: $ (0.22) $ 0.08

Revenue, Net (Tables)

Revenue, Net (Tables)	3 Months Ended
Revenue, Net (Tables)	Mar. 31, 2020
Revenue, Net [Abstract]
Schedule Of Net Revenue By Market	Timing of revenue recognition for the three months ended March 31, 2020: Products and services transferred at point in time Products and services transferred over time Total Medical: Diabetes $ - $ 13,530 $ 13,530 Other Medical (a) 1,820 1,008 2,828 Hearing Health: Value Based DTEC 1,173 - 1,173 Value Based ITEC 744 - 744 Legacy OEM 1,964 - 1,964 Professional Audio Communications: 1,264 - 1,264 Total Revenue, net $ 6,965 $ 14,538 $ 21,503 (a) During the quarter ended March 31, 2020, we recorded a cumulative adjustment of $1.2 million to reduce revenue within our other medical market to correct an error related to prior periods as a result of our determination that a portion of our sales being recognized over time needed to be recognized at a point in time. The adjustment included a reduction of the related cost of goods sold of $0.8 million and related impacts to reduce the contract asset and an increase to inventory. The adjustment was not material to our Consolidated Financial Statements for any quarterly or annual period. Timing of revenue recognition for the three months ended March 31, 2019: Products and services transferred at point in time Products and services transferred over time Total Medical: Diabetes $ - $ 17,164 $ 17,164 Other Medical - 3,629 3,629 Hearing Health: Value Based DTEC 1,630 - 1,630 Value Based ITEC 2,577 - 2,577 Legacy OEM 2,803 - 2,803 Professional Audio Communications: 1,767 - 1,767 Total Revenue, net $ 8,777 $ 20,793 $ 29,570

Discontinued Operations (Schedu

Discontinued Operations (Schedule Of Discontinued Operations Balance Sheet) (Details) - Discontinued Operations, Disposed of by Sale [Member] $ in Thousands	Dec. 31, 2019USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other current assets	$ 80
Other accrued liabilities	77
Net assets (liabilities)	$ 3

Discontinued Operations (Summar

Discontinued Operations (Summary Of Results Of Discontinued Operations) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations	$ (193)
Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net	539
Cost of goods sold	346
Gross profit	193
Sales and marketing	147
General and administrative	239
Total operating expenses	386
Loss from discontinued operations	$ (193)

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	3 Months Ended
Segment Reporting (Narrative) (Details)	Mar. 31, 2020segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting (Summary Of D

Segment Reporting (Summary Of Data By Industry Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue, net	$ 21,503	$ 29,570	$ 29,570
Income (loss) from continuing operations before income taxes and discontinued operations	(1,961)	1,099
Depreciation and amortization	921	797
Capital expenditures	1,678	938
Goodwill	9,551		9,551
Body Worn Devices [Member]
Segment Reporting Information [Line Items]
Revenue, net	20,330	27,940
Income (loss) from continuing operations before income taxes and discontinued operations	(1,078)	2,581
Depreciation and amortization	895	736
Capital expenditures	1,678	918
Identifiable assets (excluding goodwill)	99,802		101,311
Goodwill	9,551		9,551
Hearing Health DTEC [Member]
Segment Reporting Information [Line Items]
Revenue, net	1,173	1,630
Income (loss) from continuing operations before income taxes and discontinued operations	(883)	(1,482)
Depreciation and amortization	26	61
Capital expenditures		$ 20
Identifiable assets (excluding goodwill)	$ 2,365		$ 2,651

Geographic Information (Narrati

Geographic Information (Narrative) (Details) - customer	3 Months Ended		12 Months Ended
Geographic Information (Narrative) (Details) - customer	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Net Revenue [Member]
Revenue, Major Customer [Line Items]
Number of customers	1	1
Percentage of risk	63.00%	58.00%
Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Number of customers	2		2
Percentage of risk	54.00%		51.00%
Contract Assets [Member]
Revenue, Major Customer [Line Items]
Number of customers	1		1
Percentage of risk	91.00%		86.00%

Geographic Information (Geograp

Geographic Information (Geographical Distribution Of Long-Lived Assets, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 14,731	$ 13,551
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	13,421	12,215
Singapore [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	1,247	1,263
Other Geographical [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 63	$ 73

Geographic Information (Geogr_2

Geographic Information (Geographical Distribution Of Net Sales) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 21,503	$ 29,570	$ 29,570
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	17,788		24,215
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	1,187		1,664
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	2,200		3,509
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 328		$ 182

Investment In Partnerships (Nar

Investment In Partnerships (Narrative) (Details)	Mar. 31, 2020
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Equity method, ownership interest	50.00%

Investment In Partnerships (Inv

Investment In Partnerships (Investments in Partnerships) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Total	$ 750	$ 1,160
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Total	473	852
Other Investment [Member]
Schedule of Equity Method Investments [Line Items]
Total	$ 277	$ 308

Investment Securities (Narrativ

Investment Securities (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Cash	$ 14,821	$ 7,200

Investment Securities (Summary

Investment Securities (Summary Of Maturity Dates Of Investments) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 15,177	$ 8,523
Less than one year	16,889	23,451
1-5 years	5,379	8,629
Total	22,268	32,080
Commercial Paper Original Maturities of 91 Days or More [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	1,897	8,461
Total	1,897	8,461
Corporate Notes And Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	14,992	14,990
1-5 years	5,379	8,629
Total	$ 20,371	$ 23,619

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Raw materials	$ 13,924	$ 12,861
Work-in process	3,842	951
Finished products and components	1,349	2,565
Total	19,115	16,377
Domestic [Member]
Inventory [Line Items]
Raw materials	11,341	10,379
Work-in process	3,501	736
Finished products and components	1,160	2,375
Total	16,002	13,490
Foreign [Member]
Inventory [Line Items]
Raw materials	2,583	2,482
Work-in process	341	215
Finished products and components	189	190
Total	$ 3,113	$ 2,887

Other Assets, Net (Narrative) (

Other Assets, Net (Narrative) (Details) € in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2019EUR (€)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 31, 2019USD ($)
Other Assets, Net [Line Items]
Accumulated amortization		$ 28,213	$ 27,522
Period of future quarterly installments of non-cash amounts, software capitalization		4 years
Cash Paid At Closing [Member]
Other Assets, Net [Line Items]
Software, capitalized cost				$ 586
Software, Future Quarterly Installments Next Four Years [Member]
Other Assets, Net [Line Items]
Software, capitalized cost				869
Due In January 2023 [Member]
Other Assets, Net [Line Items]
Software, capitalized cost				533
Software, Value Of Partnership And License Agreement Transferred [Member]
Other Assets, Net [Line Items]
Software, capitalized cost				$ 1,691
Self-Fitting Software [Member]
Other Assets, Net [Line Items]
Accumulated amortization		$ 982	$ 884
Self-Fitting Software [Member] \| Maximum [Member]
Other Assets, Net [Line Items]
Estimated useful life		7 years
Self-Fitting Software [Member] \| Minimum [Member]
Other Assets, Net [Line Items]
Estimated useful life		5 years
Other Accrued Current Liabilities [Member]
Other Assets, Net [Line Items]
Software Purchase, Outstanding Liabilities		$ 238
Other Long Term Liabilities [Member]
Other Assets, Net [Line Items]
Software Purchase, Outstanding Liabilities		$ 857
Soundperience [Member]
Other Assets, Net [Line Items]
Payments for Software \| €	€ 1,750
Percent Of Ownership Interest Transferred	49.00%

Other Assets, Net (Schedule Of

Other Assets, Net (Schedule Of Other Assets, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Assets [Line Items]
Other assets, net	$ 5,902	$ 6,055
Self-Fitting Software [Member]
Other Assets [Line Items]
Other assets, net	3,679	3,679
Technology Access [Member]
Other Assets [Line Items]
Other assets, net	1,768	1,866
Other Assets [Member]
Other Assets [Line Items]
Other assets, net	$ 455	$ 510

Other Accrued Liabilities (Comp

Other Accrued Liabilities (Components Of Other Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Accrued Liabilities [Abstract]
Pension	$ 120	$ 120
Postretirement benefit obligation	71	71
Deferred revenue	327	327
Self-fitting software liability	238	285
Technology access liability	989	1,236
Other	729	830
Total	$ 2,474	$ 2,869

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	3 Months Ended
Leases (Narrative) (Details) $ in Thousands	Mar. 31, 2020USD ($)item	Dec. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Finance Lease, Weighted Average Discount Rate, Percent	5.56%
Finance Lease, Weighted Average Remaining Lease Term	1 year 2 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	5.26%
Operating Lease, Weighted Average Remaining Lease Term	2 years 10 months 24 days
Incremental borrowing rates terms, discount rates	5 years
Operating Lease, Payments \| $	$ 507
ROU asset \| $	3,862	$ 4,372
Lease liability \| $	$ 4,108
Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	3
Minnesota [Member] \| Lease Expiration In 2022 [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	2
Minnesota [Member] \| Lease Expiration In 2023 [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Illinois [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Singapore [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Indonesia [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
ROU asset \| $	$ 103
Lease liability \| $	$ 72
Germany [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Lessee, Operating Lease, Renewal Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Renewal Term	5 years

Leases (Summary Of Lease Costs

Leases (Summary Of Lease Costs By Type) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Amortization of right-of-use assets	$ 26	$ 25
Interest on lease liabilities	2	3
Operating lease cost	481	460
Variable lease cost	151	138
Total lease cost	$ 660	$ 626

Leases (Maturities Of Lease Lia

Leases (Maturities Of Lease Liabilities) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating Leases, 2020	$ 1,375
Operating Leases, 2021	1,567
Operating Leases, 2022	1,003
Operating Leases, 2023	396
Operating Leases, 2024	80
Operating Leases, Total lease payments	4,421
Operating Leases, Less: Interest	(313)
Operating Leases, Present value of lease liabilities	4,108
Financing Leases, 2020	73
Financing Leases, 2021	31
Financing Leases, 2022	3
Financing Leases, Total lease payments	107
Financing Leases, Less: Interest	(4)
Financing Leases, Present value of lease liabilities	103
Lease, Liability, 2020	1,448
Lease, Liability, 2021	1,598
Lease, Liability, 2022	1,006
Lease, Liability, 2023	396
Lease, Liability, 2024	80
Lease, Liability, Total lease payments	4,528
Lease, Less: Interest	(317)
Lease, Present value of lease liabilities	$ 4,211

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Income Taxes [Abstract]
Income tax expense	$ 18	$ 131
CARES Act, Employee Retention Tax Credit, Amount Per Eligible Employee	$ 5

Income Taxes (Domestic And Fore

Income Taxes (Domestic And Foreign Income Taxes (Benefits)) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Loss Carryforwards [Line Items]
(Loss) income from continuing operations before income taxes and discontinued operations	$ (1,961)	$ 1,099
United States IRS [Member]
Operating Loss Carryforwards [Line Items]
(Loss) income from continuing operations before income taxes and discontinued operations	(1,842)	885
Singapore Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
(Loss) income from continuing operations before income taxes and discontinued operations	(153)	117
Indonesia [Member]
Operating Loss Carryforwards [Line Items]
(Loss) income from continuing operations before income taxes and discontinued operations	18	21
Federal Ministry Of Finance Germany [Member]
Operating Loss Carryforwards [Line Items]
(Loss) income from continuing operations before income taxes and discontinued operations	$ 16	$ 76

Shareholders' Equity And Stoc_3

Shareholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	131		183
Number of Shares, Awards granted	66
Shares purchased for award	5	3
Stock option expense	$ 376	$ 329
Unrecognized compensation costs related to non-vested awards	$ 2,730
Unrecognized compensation costs related to non-vested awards, recognition period	2 years 1 month 17 days
Total intrinsic value of options exercised	$ 189
Maximum number of shares approved under purchase plan	300
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of Shares, Awards granted	66
Weighted average fair value of units granted	$ 17.48
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	357
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options	10 years

Shareholders' Equity And Stoc_4

Shareholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	874
Number of Shares, Awards granted	66
Number of Shares, Awards exercised or vested	(48)
Number of Shares, Outstanding	892
Number of Shares, Exercisable	695
Number of Shares, Available for future grant at beginning of period	183
Number of Shares, Available for future grant at end of period	131
Weighted-average Exercise Price, Outstanding \| $ / shares	$ 6.39
Weighted-average Exercise Price, Awards exercised or vested \| $ / shares	4.72
Weighted-average Exercise Price, Outstanding \| $ / shares	6.43
Weighted-average Exercise Price, Exercisable \| $ / shares	$ 6.37
Aggregate Intrinsic Value, Outstanding \| $	$ 5,802
Aggregate Intrinsic Value, Exercisable \| $	$ 3,751
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	746
Number of Shares, Awards exercised or vested	(15)
Number of Shares, Outstanding	731
Number of Shares, Exercisable	695
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	128
Number of Shares, Awards granted	66
Number of Shares, Awards exercised or vested	(33)
Number of Shares, Outstanding	161

Income Per Share (Narrative) (D

Income Per Share (Narrative) (Details) - shares	3 Months Ended
Income Per Share (Narrative) (Details) - shares	Mar. 31, 2020	Mar. 31, 2019
Income Per Share [Abstract]
Securities excluded from computation of diluted income per share	893	0

Income Per Share (Reconciliatio

Income Per Share (Reconciliation Between Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Per Share [Abstract]
(Loss) income from continuing operations before discontinued operations	$ (1,979)	$ 968
Loss from discontinued operations (Note 3)		(193)
Net (loss) income	$ (1,979)	$ 775
Basic - weighted shares outstanding	8,813	8,705
Weighted shares assumed upon exercise of stock awards		677
Diluted - weighted shares outstanding	8,813	9,382
Continuing operations	$ (0.22)	$ 0.11
Discontinued operations		(0.02)
Net (loss) income per share:	(0.22)	0.09
Continuing operations	(0.22)	0.10
Discontinued operations		(0.02)
Net (loss) income per share:	$ (0.22)	$ 0.08

Related-Party Transactions (Nar

Related-Party Transactions (Narrative) (Details) € in Thousands, $ in Thousands	1 Months Ended
	Jan. 31, 2019EUR (€)	Mar. 31, 2020USD ($)
Signison [Member]
Related Party Transaction [Line Items]
Equity method, ownership interest		50.00%
Note receivable \| $		$ 473
Soundperience [Member]
Related Party Transaction [Line Items]
Payments for Software \| €	€ 1,750
Percent Of Ownership Interest Transferred	49.00%

Revenue, Net (Schedule Of Net R

Revenue, Net (Schedule Of Net Revenue By Market) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 21,503	$ 29,570	$ 29,570
Cost of goods sold	16,931	21,012
Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	6,965	8,777
Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	14,538	20,793
Medical, Diabetes [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	13,530	17,164
Medical, Diabetes [Member] \| Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	13,530	17,164
Medical, Other Medical [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,828	3,629
Medical, Other Medical [Member] \| Scenario, Adjustment [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	(1,200)
Cost of goods sold	(800)
Medical, Other Medical [Member] \| Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,820
Medical, Other Medical [Member] \| Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,008	3,629
Hearing Health Value Based DTEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,173	1,630
Hearing Health Value Based DTEC [Member] \| Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,173	1,630
Hearing Health Value Based ITEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	744	2,577
Hearing Health Value Based ITEC [Member] \| Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	744	2,577
Legacy OEM [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,964	2,803
Legacy OEM [Member] \| Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,964	2,803
Professional Audio Communications [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,264	1,767
Professional Audio Communications [Member] \| Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 1,264	$ 1,767

Subsequent Events (Details)

Subsequent Events (Details) shares in Thousands, $ in Thousands	May 18, 2020USD ($)shares	May 15, 2020USD ($)employee	Jun. 30, 2020USD ($)	May 13, 2020USD ($)	Mar. 31, 2020USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of employee reduction from restructuring \| employee		35
Annual cost saving from workforce reduction		$ 2,400
Reduction in advertising expense		$ 2,000
Subsequent Event [Member] \| Emerald Medical Services Pte Ltd [Member]
Subsequent Event [Line Items]
Purchase price, paid in cash	$ 7,128
Shares issued, acquisition related \| shares	80
Shares issued in acquisition, period held in escrow account	18 months
Additional earn-out payments percent	28.00%
Subsequent Event [Member] \| Emerald Medical Services Pte Ltd [Member] \| Regulatory Approval In Japan [Member]
Subsequent Event [Line Items]
Contingent consideration amount	$ 500
Contingent consideration liability, term	12 months
Subsequent Event [Member] \| Emerald Medical Services Pte Ltd [Member] \| Net Revenue Earn-Out Payment [Member]
Subsequent Event [Line Items]
Contingent consideration, range of outcomes, value, low	$ 333
Contingent consideration, range of outcomes, value, high	1,000
Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Credit facility, maximum borrowing capacity					$ 7,000
Revolving Credit Facility [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Credit facility, maximum borrowing capacity				$ 12,000
Covenant compliance, liquidity amount				$ 15,000
Maximum [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Anticipated restructuring charge			$ 1,500
Maximum [Member] \| Subsequent Event [Member] \| Emerald Medical Services Pte Ltd [Member]
Subsequent Event [Line Items]
Revenues	11,000
Minimum [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Anticipated restructuring charge			$ 1,200
Minimum [Member] \| Subsequent Event [Member] \| Emerald Medical Services Pte Ltd [Member]
Subsequent Event [Line Items]
Revenues	$ 9,000